A Phase 2 interventional study of ACT-541468 5 mg and ACT-541468 10 mg in Insomnia Disorder, sponsored by Idorsia Pharmaceuticals Ltd.. Completed at 35 sites in 6 countries. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2020-04-13.
Sponsored by Idorsia Pharmaceuticals Ltd. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies testing daridorexant in Sleep Initiation and Maintenance Disorders — 6 open to participants now, 6 under way, none of them phase 3. daridorexant · Sleep Initiation and Maintenance Disorders.
Among the 16 studies testing daridorexant in Sleep Initiation and Maintenance Disorders, this one is the 5th largest by enrollment, is one of 2 that started in 2016, is one of 4 in phase 2, and was the 2nd registered.
2,729 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 730 are open to participants now.
Browse Sleep Initiation and Maintenance Disorders studies →6 of the 16 studies testing daridorexant in Sleep Initiation and Maintenance Disorders are open now, in 4 countries. Recruiting first, the newest first:
Brigham and Women's Hospital · Sites in United States
Ages 40–62 · Women only
University Hospital, Montpellier · Sites in France
Ages 60–85
Sterling McPherson · Sites in United States
Ages 18+
Xuanwu Hospital, Beijing · Sites in China
Ages 18–70
Institut d'Investigació Biomèdica de Bellvitge · Sites in Spain
Ages 18–99
By country, each count listing its studies:
daridorexant: first FDA approval 2022 (QUVIVIQ), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 389 Sleep Initiation and Maintenance Disorders studies recruiting now, 152 (39%) set no upper age limit and 207 (53%) stop at 75 or younger; 59 take children under 18; 108 take healthy volunteers.
This study: 18 Years to 64 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2015; this study’s year is marked. 2 started in 2016.
This study's enrollment of 360 is above the median of 68 across 2,355 interventional studies indexed under Sleep Initiation and Maintenance Disorders.
Median enrollment 165 across the 16 interventional studies. Of the 10 that completed or were terminated, 6 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 16 have an industry lead sponsor. The 9 most frequent:
Idorsia Pharmaceuticals Ltd. is the lead sponsor of 103 studies on the registry; 4 are open to participants now.
Of its 29 completed or terminated interventional studies of FDA-regulated products, 9 (31%) have results posted.
11 studies in Sleep Initiation and Maintenance Disorders by Idorsia Pharmaceuticals Ltd.: none open now, 1 under way, none of them phase 3. Of 10 finished, 6 (60%) have results posted.
Among the 11 studies in Sleep Initiation and Maintenance Disorders by Idorsia Pharmaceuticals Ltd., this one is one of 2 that started in 2016, is one of 4 in phase 2, and was the 2nd registered.
Idorsia Pharmaceuticals Ltd.’s Sleep Initiation and Maintenance Disorders studies by the year they started, since 2015.
3 of the studies testing daridorexant in Sleep Initiation and Maintenance Disorders that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07328594Legacy Health SystemImpact of Daridorexant on Sleep, Daytime Alertness, and Smoking | 2027-03-31 |
| NCT07555743Institut d'Investigació Biomèdica de BellvitgeEfficacy and Safety of Daridorexant in Patients With Major Depressive Disorder and Insomnia | 2027-04 |
| NCT05924425University Hospital, MontpellierDaridorexant to Treat Insomnia in Patients With Mild Cognitive Impairment and Mild to Moderate Alzheimer Disease | 2027-05-13 |
Add all 3 to your calendar (.ics) → With an account.
Among the 16 studies testing daridorexant in Sleep Initiation and Maintenance Disorders, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Idorsia Pharmaceuticals Ltd.’s 11 in Sleep Initiation and Maintenance Disorders:
This tab as a report to print or save as PDF → With an account.
This study evaluates the dose response of ACT-541468 on the change of WASO from baseline to Days 1 and 2, assessed by PSG.
This study consists of the following phases: screening phase; double-blind treatment phase; safety follow-up phase. Safety is monitored throughout the study.
Principal inclusion Criteria:
Principal exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Each subject receives one 5-mg ACT-541468 capusle (+ one placebo capsule), once daily in the evening for 4 weeks
Drug: ACT-541468 5 mg · Drug: Placebo 1
Each subject receives one 10-mg ACT-541468 capusle (+ one placebo capsule), once daily in the evening for 4 weeks
Drug: ACT-541468 10 mg · Drug: Placebo 1
Each subject receives one 25-mg ACT-541468 capsule (+ one placebo capsule), once daily in the evening) for 4 weeks
Drug: ACT-541468 25 mg · Drug: Placebo 1
Each subject receives two 25-mg ACT-541468 capsules, once daily in the evening for 4 weeks
Drug: ACT-541468 25 mg
Each subject receives one 10-mg zolpidem capsule (+ one placebo capusle), once daily in the evening for 4 weeks
Drug: Zolpidem · Drug: Placebo 2
Each subject receives two placebo capsules, once daily in the evening for 4 weeks
Drug: Placebo 1
Capsule for oral administration containing ACT-541468 at a strength of 5 mg
Capsule for oral administration containing ACT-541468 at a strength of 10 mg
Capsule for oral administration containing ACT-541468 at a strength of 25 mg
Over-encapsulated zolpidem tablet at a strength of 10 mg
Placebo capsules matching ACT-541468 capsules
Placebo capsules matching over-encapsulated zolpidem
Change in Wake After Sleep Onset (WASO) From Baseline to Days 1 and 2
WASO is the time in minutes spent awake after onset of persistent sleep until lights on as determined by polysomnography (PSG)
Time frame: Baseline and Days 1&2
Change in Latency to Persistent Sleep (LPS) From Baseline to Days 1 and 2
LPS is the duration of time in minutes from lights off to persistent sleep onset as determined by PSG
Time frame: Baseline and Days 1&2
Change in Subjective Latency to Sleep Onset (sLSO) From Baseline to Week 4
sLSO is the self-reported time to fall asleep, as reported in the sleep diary
Time frame: Baseline and Week 4
Change in Subjective Wake After Sleep Onset (sWASO) From Baseline to Week 4
sWASO is the self-reported time spent awake after sleep onset as reported in the sleep diary.
Time frame: Baseline and Week 4
Conducted at 38 sites in 6 countries (Germany, Hungary, Israel, Spain, Sweden, and the USA)
| Milestone | ACT-541468 5 mg | ACT-541468 10 mg | ACT-541468 25 mg | ACT-541468 50 mg | Zolpidem | Placebo |
|---|---|---|---|---|---|---|
| Started | 60 | 59 | 60 | 61 | 60 | 60 |
| Completed | 56 | 58 | 59 | 61 | 58 | 59 |
| Not completed | 4 | 1 | 1 | 0 | 2 | 1 |
| Withdrew: Withdrawal by subject | 2 | 0 | 1 | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 2 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Randomized in error | 0 | 1 | 0 | 0 | 0 | 0 |
WASO is the time in minutes spent awake after onset of persistent sleep until lights on as determined by polysomnography (PSG)
| minutes | ACT-541468 5 mg | ACT-541468 10 mg | ACT-541468 25 mg | ACT-541468 50 mg | Zolpidem | Placebo |
|---|---|---|---|---|---|---|
| Change in Wake After Sleep Onset (WASO) From Baseline to Days 1 and 2 | -28.4 ± 4.24 | -32.3 ± 4.32 | -37.7 ± 4.25 | -47.1 ± 4.21 | -29.9 ± 4.30 | -21.4 ± 4.24 |
LPS is the duration of time in minutes from lights off to persistent sleep onset as determined by PSG
| Minutes | ACT-541468 5 mg | ACT-541468 10 mg | ACT-541468 25 mg | ACT-541468 50 mg | Zolpidem | Placebo |
|---|---|---|---|---|---|---|
| Change in Latency to Persistent Sleep (LPS) From Baseline to Days 1 and 2 | -26.88 ± 45.42 | -29.31 ± 26.79 | -36.14 ± 34.34 | -36.41 ± 26.71 | -45.14 ± 32.82 | -22.02 ± 46.63 |
sLSO is the self-reported time to fall asleep, as reported in the sleep diary
| Minutes | ACT-541468 5 mg | ACT-541468 10 mg | ACT-541468 25 mg | ACT-541468 50 mg | Zolpidem | Placebo |
|---|---|---|---|---|---|---|
| Change in Subjective Latency to Sleep Onset (sLSO) From Baseline to Week 4 | -13.38 ± 27.79 | -21.07 ± 24.26 | -15.50 ± 25.51 | -23.65 ± 24.12 | -19.98 ± 19.28 | -16.32 ± 21.16 |
sWASO is the self-reported time spent awake after sleep onset as reported in the sleep diary.
| Minutes | ACT-541468 5 mg | ACT-541468 10 mg | ACT-541468 25 mg | ACT-541468 50 mg | Zolpidem | Placebo |
|---|---|---|---|---|---|---|
| Change in Subjective Wake After Sleep Onset (sWASO) From Baseline to Week 4 | -31.32 ± 33.32 | -24.35 ± 33.4 | -29.8 ± 39.88 | -35.45 ± 37.53 | -29.08 ± 27.28 | -23.61 ± 32.62 |
Collected over Data on adverse events were collected from Screening to Safety Follow-up period. Below, data are reported for treatment-emergent adverse events (TEAEs).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ACT-541468 5 mg | 0/60 (0%) | 0/60 (0%) | 21/60 (35%) |
| ACT-541468 10 mg | 0/58 (0%) | 2/58 (3.4%) | 22/58 (37.9%) |
| ACT-541468 25 mg | 0/60 (0%) | 0/60 (0%) | 23/60 (38.3%) |
| ACT-541468 50 mg | 0/61 (0%) | 1/61 (1.6%) | 21/61 (34.4%) |
| Zolpidem | 0/60 (0%) | 0/60 (0%) | 24/60 (40%) |
| Placebo | 0/60 (0%) | 0/60 (0%) | 18/60 (30%) |
| Event | ACT-541468 5 mg | ACT-541468 10 mg | ACT-541468 25 mg | ACT-541468 50 mg | Zolpidem | Placebo |
|---|---|---|---|---|---|---|
| Myocardial infarctionCardiac disorders | 0/60 | 1/58 | 0/60 | 0/61 | 0/60 | 0/60 |
| Accident at workInjury, poisoning and procedural complications | 0/60 | 1/58 | 0/60 | 0/61 | 0/60 | 0/60 |
| Craniocerebral injuryInjury, poisoning and procedural complications | 0/60 | 1/58 | 0/60 | 0/61 | 0/60 | 0/60 |
| AngioedemaSkin and subcutaneous tissue disorders | 0/60 | 0/58 | 0/60 | 1/61 | 0/60 | 0/60 |
| Event | ACT-541468 5 mg | ACT-541468 10 mg | ACT-541468 25 mg | ACT-541468 50 mg | Zolpidem | Placebo |
|---|---|---|---|---|---|---|
| HeadacheNervous system disorders | 6/60 | 5/58 | 5/60 | 5/61 | 6/60 | 1/60 |
| NasopharyngitisInfections and infestations | 2/60 | 2/58 | 0/60 | 2/61 | 5/60 | 4/60 |
| Abdominal pain upperGastrointestinal disorders | 0/60 | 1/58 | 0/60 | 1/61 | 4/60 | 1/60 |
| NauseaGastrointestinal disorders | 0/60 | 1/58 | 2/60 | 1/61 | 4/60 | 0/60 |
| FatigueGeneral disorders | 1/60 | 1/58 | 3/60 | 0/61 | 4/60 | 2/60 |
| DizzinessNervous system disorders | 1/60 | 2/58 | 0/60 | 0/61 | 4/60 | 1/60 |
| SomnolenceNervous system disorders | 3/60 | 3/58 | 4/60 | 4/61 | 3/60 | 3/60 |
| DiarrhoeaGastrointestinal disorders | 1/60 | 0/58 | 3/60 | 0/61 | 1/60 | 2/60 |
| Gait disturbanceGeneral disorders | 0/60 | 0/58 | 0/60 | 0/61 | 2/60 | 1/60 |
| Alanine aminotransferase increasedInvestigations | 0/60 | 0/58 | 2/60 | 1/61 | 0/60 | 0/60 |
| Age, Continuous(years) | ACT-541468 5 mg | ACT-541468 10 mg | ACT-541468 25 mg | ACT-541468 50 mg | Zolpidem | Placebo | Total |
|---|---|---|---|---|---|---|---|
| Median | 41 (22 to 64) | 48 (21 to 63) | 48 (18 to 64) | 46 (18 to 63) | 43 (23 to 61) | 48 (23 to 64) | 47 (18 to 64) |
| Age, Customized(Participants) | ACT-541468 5 mg | ACT-541468 10 mg | ACT-541468 25 mg | ACT-541468 50 mg | Zolpidem | Placebo | Total |
|---|---|---|---|---|---|---|---|
| Adults (18-64 years) | 60 | 58 | 60 | 61 | 60 | 60 | 359 |
| Sex: Female, Male(Participants) | ACT-541468 5 mg | ACT-541468 10 mg | ACT-541468 25 mg | ACT-541468 50 mg | Zolpidem | Placebo | Total |
|---|---|---|---|---|---|---|---|
| Female | 38 | 38 | 39 | 39 | 38 | 38 | 230 |
| Male | 22 | 20 | 21 | 22 | 22 | 22 | 129 |
| Ethnicity (NIH/OMB)(Participants) | ACT-541468 5 mg | ACT-541468 10 mg | ACT-541468 25 mg | ACT-541468 50 mg | Zolpidem | Placebo | Total |
|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 9 | 3 | 9 | 5 | 4 | 9 | 39 |
| Not Hispanic or Latino | 51 | 54 | 51 | 56 | 56 | 51 | 319 |
| Unknown or Not Reported | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
| Race (NIH/OMB)(Participants) | ACT-541468 5 mg | ACT-541468 10 mg | ACT-541468 25 mg | ACT-541468 50 mg | Zolpidem | Placebo | Total |
|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
| Black or African American | 5 | 8 | 4 | 5 | 6 | 7 | 35 |
| White | 54 | 49 | 56 | 56 | 54 | 52 | 321 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Oct 2016 to primary completion in Apr 2017, 6 months.
Results were first posted in Apr 2020, 2 years 11 months after primary completion. A results delay was requested in Apr 2018.
Of 26 industry-sponsored phase 2 interventional studies under Sleep Initiation and Maintenance Disorders, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 16. This study's 6 months is below that.
Counting every sponsor, half of 62 studies reached it within 17 months; a quarter within 12 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Daridorexant
Sleep Initiation and Maintenance Disorders →
Idorsia Pharmaceuticals Ltd. →